4519.T Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 09:15):

Stats
Объем за сегодня	4.61M
Средний объем	2.52M
Рыночная капитализация	7 983.40B
EPS	¥45.22 ( 2024-04-24 )
Дата следующего отчета о доходах	( ¥52.88 ) 2024-07-25
Last Dividend	¥40.00 ( 2023-06-29 )
Next Dividend	¥0 ( N/A )
P/E	24.45
ATR14	¥4.69 (0.10%)

Объем Корреляция

Длинно: -0.43 (neutral)

Кратко: -0.81 (strong negative)

Signal:(28.37) Be Aware. Possible trading coming up! (swing)

Chugai Pharmaceutical Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Chugai Pharmaceutical Корреляция - Валюта/Сырье

0.07
( neutral )

0.09
( neutral )

-0.02
( neutral )

-0.35
( neutral )

0.07
( neutral )

-0.31
( neutral )

Chugai Pharmaceutical Финансовые показатели

Annual	2023
Выручка:	¥1 111.37B
Валовая прибыль:	¥693.01B (62.36 %)
EPS:	¥197.83

FY	2023
Выручка:	¥1 111.37B
Валовая прибыль:	¥693.01B (62.36 %)
EPS:	¥197.83

FY	2022
Выручка:	¥1 259.95B
Валовая прибыль:	¥783.70B (62.20 %)
EPS:	¥227.64

FY	2021
Выручка:	¥999.76B
Валовая прибыль:	¥661.61B (66.18 %)
EPS:	¥184.37

Financial Reports:

No articles found.

Chugai Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥0 (N/A)	¥40.00 (N/A)	¥0 (N/A)	¥40.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Chugai Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.92 - Stable (18.39%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥0.500	2000-03-28
Last Dividend	¥40.00	2023-06-29
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	48	--
Total Paid Out	¥538.17	--
Avg. Dividend % Per Year	0.00%	--
Score	4.18	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.92
Div. Directional Score	8.99	--

Next Divdend (Est)
(2024-10-10)

¥0 Estimate 3.74 %

Dividend Stability

0.30 Very Poor

Dividend Score

4.18

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8285.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7673.T	Ex Dividend Junior	2024-05-30	Annually	0.00%
6855.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6203.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
4929.T	Ex Dividend Junior	2024-03-18	Annually	0.00%
4099.T	Ex Dividend Junior	2023-12-28	Semi-Annually	0.00%
3315.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
2384.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
9312.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
8043.T	Ex Dividend Junior	2024-03-28	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.293	1.500	4.14	6.21	[0 - 0.5]
returnOnAssetsTTM	0.168	1.200	4.39	5.26	[0 - 0.3]
returnOnEquityTTM	0.213	1.500	8.74	10.00	[0.1 - 1]
payoutRatioTTM	0.404	-1.000	5.96	-5.96	[0 - 1]
currentRatioTTM	4.74	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.68	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.591	1.500	2.27	3.40	[0.2 - 2]
debtRatioTTM	0.00696	-1.500	9.88	-10.00	[0 - 0.6]
interestCoverageTTM	16 613	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	249.36	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	204.23	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.00828	-1.500	9.97	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.628	1.000	2.86	2.86	[0.2 - 0.8]
operatingProfitMarginTTM	0.389	1.000	4.23	4.23	[0.1 - 0.6]
cashFlowToDebtRatioTTM	30.49	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.575	0.800	9.50	7.60	[0.5 - 2]
Total Score				12.05

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	24.53	1.000	7.62	0	[1 - 100]
returnOnEquityTTM	0.213	2.50	9.19	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	204.23	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	1.649	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	249.36	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.404	1.500	5.96	-5.96	[0 - 1]
pegRatioTTM	0.437	1.500	-0.422	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.369	1.000	3.27	0	[0.1 - 0.5]
Total Score				5.92

Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.